



Targeting the Unfolded Protein Response as a Disease Modifying Pathway in Dementia

Emad Sidhom^{1,2,3}, John O'Brien⁴, Adrian J Butcher^{1,2}, Heather L Smith^{1,2}, Giovanna Mallucci^{1,2}, Benjamin R Underwood^{3,4,*}

¹Department of Clinical Neurosciences, University of Cambridge, Cambridge CB2 0AH: es839@medschl.cam.ac.uk

² UK Dementia Research Institute at the University of Cambridge, Cambridge CB2 0AH, United Kingdom

³ Cambridgeshire and Peterborough NHS Foundation Trust, Windsor Research Unit, Fulbourn Hospital, Cambridge CB21 5EF

⁴ Department of Psychiatry, University of Cambridge, Herchel Smith Building, Forvie Site, Cambridge CB2 0SZ

* Correspondence: ben.underwood@cpft.nhs.uk

Abstract: Dementia is a global medical and societal challenge. It has devastating personal, social and economic costs, which will increase rapidly as the world's population ages. Despite this, there are no disease modifying treatments for dementia: current therapy modestly improves symptoms but does not change outcome. Therefore, new treatments are urgently needed, particularly any which can slow down disease progression. Many of the neurodegenerative diseases which lead to the dementia syndrome are characterized by common pathological responses to abnormal protein production and misfolding in brain cells, raising the possibility of the broad application of therapeutics that target these common processes. The unfolded protein response (UPR) is one such mechanism. The UPR is a highly conserved cellular stress response to abnormal protein folding, that is widely dysregulated in neurodegenerative diseases[1]. In this review, we describe the basic machinery of the UPR, the evidence for its over-activation and pathogenicity in dementia and for the marked neuroprotective effects of its therapeutic manipulation in mouse models of these disorders. We discuss drugs identified as potential UPR-modifying therapeutic agents, in particular the licensed antidepressant trazodone and we review epidemiological and trial data from its use in human populations. Finally, we explore future directions for investigating the potential benefit of using trazodone or similar UPR-modulating compounds for disease modification in patients with dementia.

Keywords: Dementia, Alzheimer's disease, trazodone, unfolded protein response, integrated stress response, neuroprotection, neurodegenerative disorders, neurocognitive disorders

Citation: Sidhom E.; O'Brien JT.; Butcher AJ.; Smith HL.; Mallucci GR.; Underwood BR; Targeting the Unfolded Protein Response as a Disease Modifying Pathway in Dementia. *Int. J. Mol. Sci.* **2021**, *22*, x. <https://doi.org/10.3390/xxxxx>

Academic Editor: Firstname Last-name

Received: date

Accepted: date

Published: date

Publisher's Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Copyright: © 2021 by the authors. Submitted for possible open access publication under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

1. Introduction

Disease modifying drugs for neurodegenerative diseases leading to dementia are urgently needed. In England and Wales, the annual mortality from dementia is similar in magnitude to the mortality arising from SARS-CoV-2 in 2020 at nearly 70,000 deaths per year, and greater than that for ischemic heart disease or cerebrovascular disease[2][3]. The biggest risk factor for developing dementia is advancing age [4] As the population ages, the number of cases will double every twenty years, with the majority of cases in developing countries[5]. The most common cause of dementia is Alzheimer's disease (AD), which accounts for 60-70% of all cases [6]. The current drug treatments available, such as cholinesterase inhibitors developed after initial trials of tacrine and the NMDA receptor antagonist, memantine, may ameliorate the symptoms of disease, but they do not delay its progression[7][8]. Even a modest delay in disease progression is likely to

have significant benefits: slowing the onset of AD by five years has been predicted to result in decreased disease incidence and associated costs by some 40% [9]. This would be significant at medical and societal levels, reducing personal suffering, but also economically: dementia care costs some £26 billion per year in the UK alone, which is anticipated to double in the next 25 years without disease-modifying treatments[10].

The many mechanisms driving the pathology of Alzheimer's disease are becoming increasingly understood. They include disease-specific processes, due to β -amyloid deposition, for example, as well as more generic common processes, resulting from homeostatic responses to protein aggregation, such as the unfolded protein response (UPR), dysregulated autophagy, inflammation, and oxidative stress[11,12,13,14]. These common mechanisms are gathering attention as therapeutic targets[15] due to their broad relevance across neurodegenerative diseases. Drugs in clinical use for other conditions that target these pathways include, for example, the autophagy inducer rilmenidine[16] and trazodone[17], which acts on the UPR. These are therefore prime candidates for repurposing. This review describes the cellular mechanisms and preclinical studies underpinning therapeutic approaches focusing on UPR modulation and describes evidence from epidemiology and early clinical trials using trazodone – for reasons other than disease modification – before exploring how these could be turned in to available treatments for patients with dementia.

2. The Unfolded Protein Response

The UPR is a highly conserved cellular stress response that acts to restore protein homeostasis upon accumulation of misfolded proteins in the endoplasmic reticulum (Figures 1 and 2). UPR activation results in decreased rates of protein translation, induction of chaperones and increased ER folding capacity. These outcomes are mediated by the activation of three ER resident transmembrane proteins which sense and respond to ER stress. These proteins are activating transcription factor 6 (ATF6), the inositol requiring enzyme 1 (IRE1) and protein kinase RNA-like endoplasmic reticulum kinase (PERK) [18]. Under resting conditions, the three sensors are held in an inactive state through their association with binding immunoglobulin protein (BiP) in the ER lumen. Under stress conditions BiP dissociates, preferentially binding to misfolding proteins, leading to sensor activation and initiation of the UPR signaling cascade[19]. Activated PERK, IRE1 and ATF6 signal through the transcription factors ATF4, XBP1s and ATF6N, respectively, to drive a coordinated program of transcriptional changes, up-regulating chaperones, and components of the ER-associated degradation pathway. If the source of stress cannot be resolved and UPR signaling is prolonged ATF4 upregulates pro-apoptotic C/EBP homologous protein (CHOP), initiating the apoptotic cascade[20].

Amongst the three branches of the UPR, the PERK branch is unique in that it also drives a translational response to ER stress. Activated PERK phosphorylates the α -subunit of eukaryotic initiation factor 2 (eIF2)[21], which lies at the hub of the related integrated stress response (ISR) of which the PERK branch is a key signalling pathway[22] (see Figure 2). This phosphorylation event switches eIF2 from a substrate to a non-competitive inhibitor of eIF2B – the guanine exchange factor that recycles eIF2-GDP to eIF2-GTP[23]. In the GDP bound state eIF2 is unable to form the ternary complex with initiator methionine tRNA and thus translation is inhibited at the level of initiation. This inhibition is beneficial in the short term, lowering the entry of newly synthesised proteins into the ER and reducing any additional folding burden on the organelle. The repression of translation is however transient, achieved by a negative feedback loop whereby phosphorylated eIF2 α drives the non-canonical expression of ATF4, which in turn upregulates GADD34, the regulatory subunit of the protein phosphatase 1 complex that dephosphorylates eIF2 α [24]. Dysregulation of this feedback loop and the resultant sustained repression of protein synthesis is a key neurotoxic mechanism in

neurodegenerative diseases as production of proteins essential for neuronal health and synaptic integrity are impaired[25][26][27].

3. Evidence for UPR as a key pathogenic mechanism in neurodegeneration.

Most cases of progressive neurodegenerative diseases are characterized by the misfolding of proteins which aggregate into intra-neuronal proteinaceous inclusions, such as A β and tau in Alzheimer's disease and α -synuclein in Parkinson's disease. Though most of these proteins are intracytoplasmic it is important to note the A β , though processed in the endoplasmic reticulum and Golgi, accumulates primarily in extracellular plaques, though intraneuronal accumulation has also been observed[28,29].

Post-mortem studies in patients with Alzheimer's disease, Parkinson's disease, progressive supranuclear and ALS[30,31,32] reveal markers of UPR activation, including phosphorylation of PERK and eIF2 α associated with protein aggregates [33,34] (Figure 1). Importantly, in Alzheimer's disease, this has been shown to be a feature of early disease and likely to precede tau tangle formation and paralleling misfolded protein deposition as it spreads through the brain, which makes it a promising target for therapeutic intervention[35]. Downstream mediators of cell death, such as CHOP, have also been demonstrated in human patient postmortem samples of sporadic ALS[32].

Figure (1) Markers of UPR Activation associated with Pathological Protein deposition in Neurodegenerative Disorders




Figure 1. Proteins associated with UPR activation are seen in association with protein aggregates in patients with different neurodegenerative diseases in specific brain regions. Inositol requiring enzyme 1 (IRE1) and protein kinase RNA-like endoplasmic reticulum kinase (PERK) are key sensory proteins to ER stress and are activated in frontotemporal dementia and Alzheimer's disease. p-PERK and its downstream substrate eukaryotic initiation factor 2 (eIF2), p-eIF2 α , are also activated in Parkinson's disease, Alzheimer's disease and progressive supranuclear palsy. For review, see Hetz & Saxena (2017)[1].

Mouse models of neurodegenerative diseases including prion disease, tauopathies, Alzheimer's and motor neuron disease similarly exhibit biochemical markers of UPR over-activation including sustained levels of phosphorylated PERK and eIF2 α from early disease[36][37][38][39]. The importance of the UPR in pathogenesis is shown by the remarkable clinical improvements following genetic or pharmacological inhibition of the PERK-eIF2 α pathway, due to partial restoration of global protein translation rates[25, 26,27,46,47,49]. These include rescue of memory, behavioural and motor impairments, prevention of neuronal loss and increased survival in many mouse models. The restoration of protein synthesis rates is central to neuroprotection, providing essential synaptic and other proteins necessary for memory formation and neuronal survival. In prion-diseased mice, genetic reduction of eIF2 α -P levels through over-expression of GADD34, both in neurons[25] or astrocytes[40] is profoundly neuroprotective restoring synapse number, synaptic transmission, memory and preventing neuronal loss. In the context of Alzheimer's disease models, further indirect mechanisms may be involved following UPR activation, for example, via PERK activation of glycogen synthase kinase 3 β and subsequent increased tau phosphorylation and beta amyloid precursor cleaving protein (BACE) expression, increasing amyloidogenesis [41]. Restoring protein synthesis through modulation of eIF2 α -P levels by manipulating other ISR kinases is also neuroprotective and boosts cognition[42][43][44]. For example, genetic modulation of signaling through PERK and another ISR eIF2 α kinase, GCN2, reduce levels of eIF2 α -P and is protective in mouse models of Alzheimer's disease, restoring memory and cognitive function [39]. In Down syndrome mice, genetic modulation of PKR signaling restores memory and corrects translational deficits [46].

4. Drugs Targeting UPR and ISR

The PERK inhibitor, GSK2606414, is profoundly neuroprotective in murine models of prion disease[47] and has shown improvement in Parkinson's disease[48] and FTD mouse models[27] and fly models of amyotrophic lateral sclerosis (ALS) [49], while salubrinal, an inhibitor of eIF2 α dephosphorylation has the opposite effect[25] (see Figure 2). The clinical 'cure' seen in these animal models is associated with decreased synapse and neuronal loss, mediated by restoring protein synthesis rates. However, the clinical utility of GSK2606414 is limited by its systemic (pancreatic) toxicity, precluding its use in humans. The small molecule ISRIB (integrated stress response inhibitor B) acts downstream of phosphorylated eIF2 α , preventing its interaction with its target, eIF2B and restores neuronal protein synthesis rates without toxic effects on the pancreas [50,51]. ISRIB boosts memory in wild type mice and is neuroprotective and/or enhances cognition in a variety of mouse models of neurodegenerative diseases[52,53,54,55]. It has been shown to increase hippocampal protein production and rescue disease phenotypes in Alzheimer mouse models, but its low level of solubility limits its applicability for human use [56]. To find safe alternatives with similar efficacy on UPR inhibition as ISRIB, Halliday and colleagues screened an NINDS library of drugs which largely have FDA approval and are known to be neurologically active. They identified dibenzoylmethane (DBM) and the licensed anti-depressant trazodone as compounds able to cross the blood brain barrier, restore protein synthesis rates and profoundly improve memory and survival in prion diseased mice and a frontotemporal dementia mouse model by acting downstream of eIF2 α phosphorylation, similar to ISRIB[17]. Trazodone is a phenyl piperazine derivative

which has a range of agonist and antagonist activity including antagonism at 5HT2 receptors and agonism at 5HT1A receptors in addition to adrenergic and histaminergic activity and serotonin uptake inhibition. It is a particularly promising drug as it has a long record of human use, including in neurodegenerative disease, for example in sleep disturbance in Alzheimer's disease[57]

Trazodone may have pleiotropic therapeutic mechanisms including effects on tau and restoration of slow wave sleep [58,59]. Other drugs which impact on the UPR have been developed and some have now entered clinical trials, for example guanabenz in amyotrophic lateral sclerosis[60]. Guanabenz, like salubrinal and sephin-1 in pre-clinical studies[61], reduces ER stress and protein overload, through a mechanism opposite to that of trazodone and ISRIB as it leads to increased levels of phosphorylated eIF2 α . This allows increased chaperone expression and has proven efficacy in some mouse models of ALS and in the rare hereditary neuropathy CMT1b[62,63,64], underlining the importance of the UPR in these disorders and highlighting the need to understand the complex mechanisms and outcomes of drugs acting on the pathway.

Figure (2): Schematic showing points of action of drugs and experimental compounds targeting the PERK branch of the UPR and ISR.




Figure 2. (1) The chaperone protein, binding immunoglobulin protein (BiP), binds to misfolded proteins resulting in (2) phosphorylation of PERK. PERK activation in turn leads to (3) phosphorylation of eIF2 α , which reduces protein translation (4) via by preventing nucleotide exchange by eIF2B needed for initiation of translation. GSK260414 inhibits PERK phosphorylation; ISRIB prevents eIF2B binding by p-eIF2 α and trazodone also acts downstream of p-eIF2 α by restoring global protein synthesis rates. Intervention at all these steps provides exceptional neuroprotection in many animal models of neurodegenerative disease.

5. Epidemiological data from observational studies on trazodone use in dementia

Given the efficacy of trazodone for neuroprotection in animal models and its wide availability in clinical practice, its potential for repurposing for the treatment of dementia appears clear. Its widespread clinical use for many years allows examination of the

literature to yield valuable information on 1) safety of use of trazodone and 2) any potential disease modifying effects, or lack of them, of trazodone use in dementia.

Studies looking at safety in large prescribing data sets show trazodone to be similar to atypical antipsychotics and benzodiazepines in terms of fall and fracture risk in demented patients, but with a lower overall mortality risk [65,66]. The largest study of cardiac side effects of trazodone in older people found no effect on QTc and minimal effect on pulse or other ECG parameters [67,68]. Similarly, trazodone may be less likely to result in hyponatraemia than other antidepressants [69].

In terms of disease-modifying effects of trazodone in dementia, several recent studies have looked at naturalistic data sets, with largely negative results. An investigation of over 4,000 trazodone users matched to patients prescribed other antidepressants found a higher overall incidence of dementia diagnosis in the trazodone group, though did not suggest a causal association[70]. This study included patients over 50 years of age prescribed trazodone on two or more consecutive occasions at any time over 17 years. Around a third of patients had a diagnosis of depression. A second study examined routinely collected data from 406 patients with a diagnosis of dementia who were prescribed trazodone and followed up for an average of 2.2 years, with cognitive testing every 4-6 months. No positive impact of trazodone on cognition compared to other antidepressants was found in this study either[71]. Two points are worth noting here. First, the patient group had moderately advanced disease on entry to the study (mean baseline MMSE 13.7-18.1 in those prescribed trazodone across three sites) and moderate/advanced disease may be beyond the point of possible positive impact - preclinical studies all test the drug and related interventions in relatively early, rather than advanced disease. Second, the mean dose of trazodone used was 100mg; the trazodone dose predicted to impact the UPR in man is calculated to be around 200mg, using surface area normalization formulae used to convert from effective doses in mice[17]. A further observational study found an improvement in the neuropsychiatric inventory, but not in cognition, in patients with Alzheimer's disease treated with trazodone over 12 months, though the numbers of patients was small, including only eight patients on trazodone, their MMSE score at baseline was 20.0 ± 5 , and at 12 months was 19.9 ± 5 [72]. While these are very interesting, well-conducted observational studies, they preclude testing the hypothesis of whether trazodone influences cognitive decline in early disease at UPR-effective doses.

Interestingly, in a targeted observational study, 25 trazodone users with early Alzheimer's disease (MMSE>20), mild cognitive impairment or normal cognition attending a sleep clinic over four years were compared to 25 matched controls that did not take the drug. Trazodone users showed improvements in sleep and cognition, notably, with significantly slower decline in MMSE over an average duration of four years [59]. Despite the small size of this study, it does suggest that refining the target patient population to early/mild Alzheimer's disease or even MCI, combined with longer follow up in randomized controlled clinical trials, would better elucidate any effect - or lack of this - of trazodone on progression of cognitive decline in early dementia.

Overall, observational studies can only ever show associations and have many confounding variables. For example, trazodone is an unusual choice of antidepressant for older people[70], and it may be prescribed preferentially in those with symptoms suggestive of incipient dementia (for example sleep disturbance[73]) or in established dementia for those with behavioral symptoms which are associated with more advanced disease[74] [71], both of which could mask any benefits of the drug. In a recent study of 465,628 patients over 50 prescribed antidepressants, only 4,596 (<1%) were prescribed trazodone as first line treatment, suggesting it is not a common therapeutic choice [70]. In another study, the most common reason for starting trazodone was agitation, which is more common later in the disease course [71].

In summary, the literature from observational studies of trazodone effects in dementia provides a conflicting picture with limited support to date for any disease-modifying

effect of trazodone. This is perhaps not surprising, as these studies do not report data designed to test the efficacy of trazodone in this context. To properly test the effects of an intervention and causation the only definitive study design is a randomized controlled trial.

6. Clinical trial data on trazodone use in older adults, including individuals with dementia

Trazodone has been trialed extensively since the 1970s for efficacy in major depressive disorder[75] (including geriatric and post stroke populations[76]), pain[77], sleep[78], erectile dysfunction[79], akathisia[80], migraine[81], adjustment disorder[82], bulimia[83], oesophageal contraction abnormalities[84], OCD[85], generalized anxiety[86] and alcohol withdrawal[87][88]. The data from these trials provides important safety data on trazodone use.

In dementia, clinical trials of trazodone have largely focused on neuropsychiatric symptoms and sleep, not disease modification – trazodone is not licensed for the latter. A trial in which 28 patients with Alzheimer's disease were treated for agitation with haloperidol or trazodone (mean trazodone dose 218mg) for 9 weeks found no difference in effect between the two on agitation, although trazodone was better tolerated[89]. 30 AD patients treated with trazodone or placebo for two weeks showed improvement in sleep with trazodone [90] and in a further small trial, trazodone improved neuropsychiatric inventory (NPI) scores in frontotemporal dementia[89].

The largest trial of trazodone on behaviour in the context of dementia involved randomization of 150 Alzheimer's patients to either haloperidol, trazodone (mean dose 200mg, range 50mg-300mg), behavioral intervention or placebo for 16 weeks and found no impact of trazodone on agitation [91]. Crucially, however, this study did demonstrate the feasibility of treating AD patients with trazodone at a dose of 200mg with few drop-outs and a side effect profile similar to placebo. Indeed, these studies are all encouraging with regards to tolerability of trazodone in this patient group. However, they were all delivered over a short time period and in moderately to severely advanced disease (for example MMSE<12 in the largest study[91]) and often at lower doses than those thought to impact the UPR. Two small studies - in 13 Alzheimer's patients and 26 frontotemporal dementia patients – also measured cognition as an outcome of trazodone treatment. No change in mini-mental state examination (MMSE) was found in either of these[92][90] after 10 and 12 weeks treatment respectively. The largest study to date which included 37 patients taking trazodone, found trazodone to have a worse cognitive outcome as measured by MMSE compared to behavioural management for agitation in Alzheimer's disease, but trazodone was not significantly different on this measure compared to placebo after 16 weeks of treatment [91]. Both clinical trials and observational studies on the effect of trazodone on cognition in healthy controls and patients with a variety of conditions, including dementia, have been the subject of a recent systematic review which described, respectively, 4 studies demonstrating impaired cognition with trazodone, 7 showing no effect, and 5 showing cognitive improvement, although the longest treatment period included was 16 weeks for interventional studies[93].

Taken together, clinical trial data so far support the tolerability of trazodone in patients suffering from dementia, including at predicted potentially UPR-modifying doses of 200mg [17]. In none to date, has trazodone been tried at early-stage disease, over a sufficient number of months/years and at the correct dose to draw any conclusions about its potential for disease modification. Most published trials of trazodone in dementia are for duration of treatment measured in weeks, and none reach consensus statements for clinical trials of disease modifying drugs in dementia which stipulate a minimum trial duration of 18 months [94] New studies are underway, including in motor neuron disease (MND/ALS) where trazodone was chosen as one of the first two drugs to be entered

into a multi-center UK adaptive trial (MND-SMART)[95] to identify disease modifying drugs in this condition, based on evidence from the most promising neuroprotective compounds in mouse models of ALS [96].

7. Future Directions

In summary, over-activation of the UPR, in particular the PERK/eIF2 α pathway, appears to be implicated in the pathogenesis of Alzheimer's disease and related disorders in human patients and there is compelling evidence for its role in mediating neurodegeneration in pre-clinical studies. Further, the profound neuroprotective effects of UPR modulation in multiple mouse models of disease and the efficacy in boosting cognition in aged and wild type mice have led to a major drive for drug discovery on this pathway. The licensed drug trazodone acts on the pathway and could be rapidly repurposed, bypassing years of drug discovery and early phase clinical trials. Observational studies and clinical trials in patient populations taking trazodone do not clearly signal a protective or disease modifying effect, but these are beset with confounding factors and are ill-placed to identify disease modifying effects due to populations studied, duration of treatment, dosage and outcomes used. Ultimately only a randomized, placebo-controlled clinical trial of trazodone or similar compounds in patients will answer the question as to whether this approach does bring relevant clinical benefits. Given the extensive preclinical data identifying the UPR as a therapeutic target in neurodegenerative disease, the efficacy of trazodone in many mouse models, together with its long track record of safe use in humans, trazodone should now be tested in experimental medicine studies in human patients. Key mechanistic questions include whether impaired cerebral protein synthesis rates – as occurs in mouse models - can be demonstrated in patient brains using in vivo readouts, at what stage in the disease such a decline (if present) can be detected, whether trazodone can restore cerebral protein synthesis in patients – and whether this protects cognition. With or without such mechanistic data, if trazodone is shown to be successful in clinical trials, it could represent the first disease modifying drug for dementia and one which could be rapidly and widely available due to its established nature and low cost, an outcome which would have a major clinical impact world-wide.

Author Contributions: BRU and GM developed the concept for the review. All authors contributed to the writing and revisions.

Acknowledgments: NIHR Cambridge Biomedical Research Centre (BRC-1215-20014) (JOB). UK Dementia Research Institute (funded by the Medical Research Council UK, Alzheimer's Research UK and the Alzheimer's Society) (G.R.M., H.S.), the Cambridge Centre for Parkinson-Plus (G.R.M. and A.B.) the European Research Council (consolidator grant UPR Neuro; no. 647479), the Joint Programme Neurodegenerative Disease, the Centres of Excellence in Neurodegeneration and the Wellcome Trust Collaborative Award (G.R.M). Gnodde Goldman Sachs Translational Neuroscience (B.U & E.S)

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Hetz C, Saxena S (2017) ER stress and the unfolded protein response in neurodegeneration. *Nat Rev Neurol* 2017 138 13:477–491. <https://doi.org/10.1038/nrneurol.2017.99>
2. Total deaths in the UK in 2020 and deaths from heart attacks, heart disease, cancer, and Alzheimer's and dementia, 2016 to 2020 - Office for National Statistics. <https://www.ons.gov.uk/aboutus/transparencyandgovernance/freedomofinformationfoi/totaldeathsintheukin2020anddeathsfromheartattacksheartdiseasecancerandalzheimersanddementia2016to2020>. Accessed 23 Dec 2021
3. Deaths due to dementia | Dementia Statistics Hub. <https://www.dementiastatistics.org/statistics/deaths-due-to-dementia/>.

- Accessed 23 Jun 2021 357
4. Ritchie K, Kildea D (1995) Is senile dementia “age-related” or “ageing-related”?--evidence from meta-analysis of dementia prevalence in the oldest old. *Lancet* (London, England) 346:931–934. [https://doi.org/10.1016/S0140-6736\(95\)91556-7](https://doi.org/10.1016/S0140-6736(95)91556-7) 358
359
 5. Ferri CP, Prince M, Brayne C, et al (2005) Global prevalence of dementia: A Delphi consensus study. *Lancet* 366:2112–2117. [https://doi.org/10.1016/S0140-6736\(05\)67889-0](https://doi.org/10.1016/S0140-6736(05)67889-0) 360
361
 6. (2020) 2020 Alzheimer’s disease facts and figures. *Alzheimer’s Dement* 16:391–460. <https://doi.org/10.1002/alz.12068> 362
 7. Herrmann N, Chau SA, Kircanski I, Lanctôt KL (2011) Current and emerging drug treatment options for alzheimers disease: A systematic review. *Drugs* 71:2031–2065 363
364
 8. Gauthier S, Bouchard R, Lamontagne A, et al (1990) Tetrahydroaminoacridine-lecithin combination treatment in patients with intermediate-stage Alzheimer’s disease. Results of a Canadian double-blind, crossover, multicenter study. *N Engl J Med* 322:1272–1276. <https://doi.org/10.1056/NEJM199005033221804> 365
366
367
 9. Zissimopoulos J, Crimmins E, St.clair P (2015) The value of delaying alzheimer’s disease onset. *Forum Heal Econ Policy* 18:25–39. <https://doi.org/10.1515/fhep-2014-0013> 368
369
 10. Dementia UK report | Alzheimer’s Society. <https://www.alzheimers.org.uk/about-us/policy-and-influencing/dementia-uk-report#:~:text=The total cost of dementia,services for state funded care.> Accessed 23 Jun 2021 370
371
 11. Ravikumar B, Futter M, Jahreiss L, et al (2009) Mammalian macroautophagy at a glance. *J Cell Sci.* <https://doi.org/10.1242/jcs.031773> 372
373
 12. Halliday M, Hughes D, Mallucci GR (2017) Fine-tuning PERK signaling for neuroprotection. *J. Neurochem.* 374
 13. Glass CK, Saijou K, Winner B, et al (2010) Mechanisms underlying inflammation in neurodegeneration. *Cell* 140:918–934. <https://doi.org/10.1016/J.CELL.2010.02.016> 375
376
 14. Yarbeygi H, Panahi Y, Javadi B, Sahebkar A (2018) The Underlying Role of Oxidative Stress in Neurodegeneration: A Mechanistic Review. *CNS Neurol Disord Drug Targets* 17:207–215. <https://doi.org/10.2174/1871527317666180425122557> 377
378
 15. Mullard A (2019) NLRP3 inhibitors stoke anti-inflammatory ambitions. *Nat Rev Drug Discov* 18:405–408 379
 16. Underwood BR, Green-Thompson ZW, Pugh PJ, et al (2017) An open-label study to assess the feasibility and tolerability of rilmenidine for the treatment of Huntington’s disease. *J Neurol* 264:2457–2463. <https://doi.org/10.1007/s00415-017-8647-0> 380
381
 17. Halliday M, Radford H, Zents KAMM, et al (2017) Repurposed drugs targeting eIF2 α -P-mediated translational repression prevent neurodegeneration in mice. *Brain* 140:1768–1783. <https://doi.org/10.1093/brain/awx074> 382
383
 18. Hetz C (2012) The unfolded protein response: Controlling cell fate decisions under ER stress and beyond. *Nat. Rev. Mol. Cell Biol.* 13:89–102 384
385
 19. Bertolotti A, Zhang Y, Hendershot LM, et al (2000) Dynamic interaction of BiP and ER stress transducers in the unfolded-protein response. *Nat Cell Biol* 2:326–332. <https://doi.org/10.1038/35014014> 386
387
 20. FAWCETT TW, MARTINDALE JL, GUYTON KZ, et al (1999) Complexes containing activating transcription factor (ATF)/cAMP-responsive-element-binding protein (CREB) interact with the CCAAT/enhancer-binding protein (C/EBP)–ATF composite site to regulate Gadd153 expression during the stress response. *Biochem J* 339:135–141. <https://doi.org/10.1042/BJ3390135> 388
389
390
391
 21. Fawcett TW, Martindale JL, Guyton KZ (1999) Protein translation and folding are coupled by an endoplasmic-reticulum-resident kinase. *Nature* 397:271–274. <https://doi.org/10.1038/16729> 392
393
 22. Costa-Mattioli M, Walter P (2020) The integrated stress response: From mechanism to disease. *Science* 368:. https://doi.org/10.1126/SCIENCE.AAT5314/ASSET/A635ADD8-C851-43C7-B4DF-D6F7503D97D5/ASSETS/GRAPHIC/368_AAT5314_FA.JPEG 394
395
396
 23. Kashiwagi K, Takahashi M, Nishimoto M, et al (2016) Crystal structure of eukaryotic translation initiation factor 2B. *Nature* 531:122–125. <https://doi.org/10.1038/NATURE16991> 397
398

24. Ma Y, Hendershot LM (2003) Delineation of a Negative Feedback Regulatory Loop That Controls Protein Translation during Endoplasmic Reticulum Stress *. *J Biol Chem* 278:34864–34873. <https://doi.org/10.1074/JBC.M301107200>
25. Moreno JA, Radford H, Peretti D, et al (2012) Sustained translational repression by eIF2 α -P mediates prion neurodegeneration. *Nature*. <https://doi.org/10.1038/nature11058>
26. Moreno JA, Halliday M, Molloy C, et al (2013) Oral treatment targeting the unfolded protein response prevents neurodegeneration and clinical disease in prion-infected mice. *Sci Transl Med*. <https://doi.org/10.1126/scitranslmed.3006767>
27. Radford H, Moreno JA, Verity N, et al (2015) PERK inhibition prevents tau-mediated neurodegeneration in a mouse model of frontotemporal dementia. *Acta Neuropathol*. <https://doi.org/10.1007/s00401-015-1487-z>
28. LaFerla FM, Green KN, Oddo S (2007) Intracellular amyloid-beta in Alzheimer's disease. *Nat Rev Neurosci* 8:499–509. <https://doi.org/10.1038/NRN2168>
29. Del Prete D, Suski JM, Oulès B, et al (2017) Localization and Processing of the Amyloid- β Protein Precursor in Mitochondria-Associated Membranes. *J Alzheimers Dis* 55:1549–1570. <https://doi.org/10.3233/JAD-160953>
30. Hoozemans JJM, van Haastert ES, Eikelenboom P, et al (2007) Activation of the unfolded protein response in Parkinson's disease. *Biochem Biophys Res Commun* 354:707–711. <https://doi.org/10.1016/J.BBRC.2007.01.043>
31. Stutzbach LD, Xie SX, Naj AC, et al (2013) The unfolded protein response is activated in disease-affected brain regions in progressive supranuclear palsy and Alzheimer's disease. *Acta Neuropathol Commun* 1:. <https://doi.org/10.1186/2051-5960-1-31>
32. Ito D, Fujisawa T, Iida H, Suzuki N (2008) Characterization of seipin/BSCL2, a protein associated with spastic paraplegia 17. *Neurobiol Dis* 31:266–277. <https://doi.org/10.1016/J.NBD.2008.05.004>
33. Hoozemans JJM, Van Haastert ES, Nijholt DAT, et al (2009) The unfolded protein response is activated in pretangle neurons in alzheimer's disease hippocampus. *Am J Pathol* 174:1241–1251. <https://doi.org/10.2353/ajpath.2009.080814>
34. Hoozemans JJM, Van Haastert ES, Nijholt DAT, et al (2012) Activation of the unfolded protein response is an early event in Alzheimer's and Parkinson's disease. *Neurodegener. Dis*. 10:212–215
35. Murray HC, Dieriks BV, Swanson MEV, et al (2020) The unfolded protein response is activated in the olfactory system in Alzheimer's disease. *Acta Neuropathol Commun* 8:109. <https://doi.org/10.1186/s40478-020-00986-7>
36. Duran-Aniotz C, Cornejo VH, Espinoza S, et al (2017) IRE1 signaling exacerbates Alzheimer's disease pathogenesis. *Acta Neuropathol* 134:489–506. <https://doi.org/10.1007/s00401-017-1694-x>
37. Abisambra JF, Jinwal UK, Blair LJ, et al (2013) Tau accumulation activates the unfolded protein response by impairing endoplasmic reticulum-associated degradation. *J Neurosci* 33:9498–9507. <https://doi.org/10.1523/JNEUROSCI.5397-12.2013>
38. Devi L, Ohno M (2014) PERK mediates eIF2 α phosphorylation responsible for BACE1 elevation, CREB dysfunction and neurodegeneration in a mouse model of Alzheimer's disease. *Neurobiol Aging* 35:2272–2281. <https://doi.org/10.1016/j.neurobiolaging.2014.04.031>
39. Saxena S, Cabuy E, Caroni P (2009) A role for motoneuron subtype-selective ER stress in disease manifestations of FALS mice. *Nat Neurosci* 12:627–636. <https://doi.org/10.1038/nn.2297>
40. Smith HL, Freeman OJ, Butcher AJ, et al (2020) Astrocyte Unfolded Protein Response Induces a Specific Reactivity State that Causes Non-Cell-Autonomous Neuronal Degeneration. *Neuron* 105:855–866.e5. <https://doi.org/10.1016/J.NEURON.2019.12.014>
41. Moradi Majd R, Mayeli M, Rahmani F (2020) Pathogenesis and promising therapeutics of Alzheimer disease through eIF2 α pathway and correspondent kinases. *Metab. Brain Dis*. 35:1241–1250
42. Costa-Mattioli M, Gobert D, Stern E, et al (2007) eIF2 α Phosphorylation Bidirectionally Regulates the Switch from Short- to Long-Term Synaptic Plasticity and Memory. *Cell* 129:195–206. <https://doi.org/10.1016/J.CELL.2007.01.050/ATTACHMENT/72A0C20F-D91D-4A6F-B0F1-26D2B804CEA7/MMC1.PDF>

43. Zhu PJ, Huang W, Kalikulov D, et al (2011) Suppression of PKR Promotes Network Excitability and Enhanced Cognition by Interferon- γ -Mediated Disinhibition. *Cell* 147:1384–1396. <https://doi.org/10.1016/J.CELL.2011.11.029>
44. Ma T, Trinh MA, Wexler AJ, et al (2013) Suppression of eIF2 α kinases alleviates Alzheimer's disease-related plasticity and memory deficits. *Nat Neurosci* 16:1299–1305. <https://doi.org/10.1038/nn.3486>
45. Krukowski K, Nolan A, Frias ES, et al (2020) Small molecule cognitive enhancer reverses age-related memory decline in mice. *Elife* 9:1–22. <https://doi.org/10.7554/ELIFE.62048>
46. Zhu PJ, Khatiwada S, Cui Y, et al (2019) Activation of the ISR mediates the behavioral and neurophysiological abnormalities in Down syndrome. *Science* 366:843–849. <https://doi.org/10.1126/SCIENCE.AAW5185>
47. Koren SA, Hamm MJ, Cloyd R, et al (2021) Broad kinase inhibition mitigates early neuronal dysfunction in tauopathy. *Int J Mol Sci* 22:1–17. <https://doi.org/10.3390/ijms22031186>
48. Mercado G, Castillo V, Soto P, et al (2018) Targeting PERK signaling with the small molecule GSK2606414 prevents neurodegeneration in a model of Parkinson's disease. *Neurobiol Dis* 112:136–148. <https://doi.org/10.1016/J.NBD.2018.01.004>
49. Hughes D, Mallucci GR (2019) The unfolded protein response in neurodegenerative disorders – therapeutic modulation of the PERK pathway. *FEBS J*.
50. Sidrauski C, Acosta-Alvear D, Khoutorsky A, et al (2013) Pharmacological brake-release of mRNA translation enhances cognitive memory. *Elife* 2:. <https://doi.org/10.7554/ELIFE.00498>
51. Sidrauski C, McGeachy AM, Ingolia NT, Walter P (2015) The small molecule ISRIB reverses the effects of eIF2 α phosphorylation on translation and stress granule assembly. *Elife* 4:. <https://doi.org/10.7554/ELIFE.05033>
52. Wong YL, LeBon L, Edalji, et al (2018) The small molecule ISRIB rescues the stability and activity of Vanishing White Matter Disease eIF2B mutant complexes. *Elife* 7:. <https://doi.org/10.7554/ELIFE.32733>
53. Westergard T, McAcoy K, Russell K, et al (2019) Repeat-associated non-AUG translation in C9orf72-ALS/FTD is driven by neuronal excitation and stress. *EMBO Mol Med* 11:. <https://doi.org/10.15252/EMMM.201809423>
54. Chou A, Krukowski K, Jopson T, et al (2017) Inhibition of the integrated stress response reverses cognitive deficits after traumatic brain injury. *Proc Natl Acad Sci U S A* 114:E6420–E6426. <https://doi.org/10.1073/PNAS.1707661114>
55. Halliday M, Radford H, Sekine Y, et al (2015) Partial restoration of protein synthesis rates by the small molecule ISRIB prevents neurodegeneration without pancreatic toxicity. *Cell Death Dis* 6:. <https://doi.org/10.1038/cddis.2015.49>
56. Oliveira MM, Lourenco M V., Longo F, et al (2021) Correction of eIF2-dependent defects in brain protein synthesis, synaptic plasticity, and memory in mouse models of Alzheimer's disease. *Sci Signal* 14:. <https://doi.org/10.1126/scisignal.abc5429>
57. McCleery J, Sharpley AL (2020) Pharmacotherapies for sleep disturbances in dementia. *Cochrane Database Syst. Rev.* 2020
58. Akbari V, Ghobadi S, Mohammadi S, Khodarahmi R (2020) The antidepressant drug; trazodone inhibits Tau amyloidogenesis: Prospects for prophylaxis and treatment of AD. *Arch Biochem Biophys* 679:108218. <https://doi.org/10.1016/j.abb.2019.108218>
59. La AL, Walsh CM, Neylan TC, et al (2019) Long-Term Trazodone Use and Cognition: A Potential Therapeutic Role for Slow-Wave Sleep Enhancers. *J Alzheimer's Dis* 67:911–921. <https://doi.org/10.3233/JAD-181145>
60. Dalla Bella E, Bersano E, Antonini G, et al (2021) The unfolded protein response in amyotrophic lateral sclerosis: results of a phase 2 trial. *Brain* 144:2635–2647. <https://doi.org/10.1093/BRAIN/AWAB167>
61. Vaccaro A, Patten SA, Aggad D, et al (2013) Pharmacological reduction of ER stress protects against TDP-43 neuronal toxicity in vivo. *Neurobiol Dis* 55:64–75. <https://doi.org/10.1016/J.NBD.2013.03.015>
62. Jiang HQ, Ren M, Jiang HZ, et al (2014) Guanabenz delays the onset of disease symptoms, extends lifespan, improves motor performance and attenuates motor neuron loss in the SOD1 G93A mouse model of amyotrophic lateral sclerosis. *Neuroscience* 277:132–138. <https://doi.org/10.1016/J.NEUROSCIENCE.2014.03.047>
63. Wang MD, Gomes J, Cashman NR, et al (2014) Intermediate CAG Repeat Expansion in the ATXN2 Gene Is a Unique Genetic Risk Factor for ALS—A Systematic Review and Meta-Analysis of Observational Studies. *PLoS One* 9:e105534.

- <https://doi.org/10.1371/JOURNAL.PONE.0105534> 483
64. Das MM, Svendsen CN (2015) Astrocytes show reduced support of motor neurons with aging that is accelerated in a rodent model of ALS. *Neurobiol Aging* 36:1130–1139. <https://doi.org/10.1016/J.NEUROBIOLAGING.2014.09.020> 484
485
 65. Watt JA, Gomes T, Bronskill SE, et al (2018) Comparative risk of harm associated with trazodone or atypical antipsychotic use in older adults with dementia: A retrospective cohort study. *CMAJ* 190:E1376–E1383. <https://doi.org/10.1503/cmaj.180551> 486
487
 66. Bronskill SE, Campitelli MA, Iaboni A, et al (2018) Low-Dose Trazodone, Benzodiazepines, and Fall-Related Injuries in Nursing Homes: A Matched-Cohort Study. *J Am Geriatr Soc* 66:1963–1971. <https://doi.org/10.1111/jgs.15519> 488
489
 67. Tellone V, Rosignoli MT, Picollo R, et al (2020) Effect of 3 Single Doses of Trazodone on QTc Interval in Healthy Subjects. *J Clin Pharmacol*. <https://doi.org/10.1002/jcph.1640> 490
491
 68. Armstrong SEM, Brown HK, Shorey C, et al (2019) No Association between Trazodone and Corrected-QT Prolongation in Older Adults. *J. Clin. Psychopharmacol.* 39:528–530 492
493
 69. Viramontes TS, Truong H, Linnebur SA (2016) Antidepressant-induced hyponatremia in older adults. *Consult. Pharm.* 31:139–150 494
495
 70. Brauer R, Lau WCY, Hayes JF, et al (2019) Trazodone use and risk of dementia: A population-based cohort study. *PLoS Med* 16:. <https://doi.org/10.1371/journal.pmed.1002728> 496
497
 71. Sommerland A, Werbeloff N, Perera G, et al (2021) Effect of trazodone on cognitive decline in people with dementia: Cohort study using UK routinely collected data. *Int J Geriatr Psychiatry*. <https://doi.org/10.1002/GPS.5625> 498
499
 72. Pirker-Kees A, Dal-Bianco P, Schmidt R (2019) Effects of Psychotropic Medication on Cognition, Caregiver Burden, and Neuropsychiatric Symptoms in Alzheimer’s Disease over 12 Months: Results from a Prospective Registry of Dementia in Austria (PRODEM). *J Alzheimer’s Dis* 71:623–630. <https://doi.org/10.3233/JAD-181102> 500
501
502
 73. Matsumoto S, Tsunematsu T (2021) Association between Sleep, Alzheimer’s, and Parkinson’s Disease. *Biology (Basel)* 10:. <https://doi.org/10.3390/BIOLOGY10111127> 503
504
 74. Charernboon T, Phanasathit M (2014) Prevalence of Neuropsychiatric Symptoms in Alzheimer’s Disease: A Cross-Sectional Descriptive Study in Thailand. *J Med Assoc Thail* 97:560 505
506
 75. Fagiolini A, Comandini A, Dell’Osso MC, Kasper S (2012) Rediscovering trazodone for the treatment of major depressive disorder. *CNS Drugs* 26:1033–1049 507
508
 76. Reding MJ, Orto LA, Winter SW, et al (1986) Antidepressant Therapy After Stroke: A Double-blind Trial. *Arch Neurol* 43:763–765. <https://doi.org/10.1001/archneur.1986.00520080011011> 509
510
 77. Tammiala-Salonen, Tuulikki . Forssell H (1999) Trazodone in burning mouth pain: A placebo-controlled, double-blind study. *J Prosthet Dent* 82:578. [https://doi.org/10.1016/s0022-3913\(99\)70067-3](https://doi.org/10.1016/s0022-3913(99)70067-3) 511
512
 78. Kaynak H, Kaynak D, Gözükmizi E, Guilleminault C (2004) The effects of trazodone on sleep in patients treated with stimulant antidepressants. *Sleep Med* 5:15–20. <https://doi.org/10.1016/j.sleep.2003.06.006> 513
514
 79. Meinhardt W, Schmitz PIM, Kropman RF, et al (1997) Trazodone, a double blind trial for treatment of erectile dysfunction. *Int J Impot Res* 9:163–165. <https://doi.org/10.1038/sj.ijir.3900272> 515
516
 80. Stryker R, Rosenzwaig S, Bar F, et al (2010) Trazodone for the treatment of neuroleptic-induced acute akathisia: A placebo-controlled, double-blind, crossover study. *Clin Neuropharmacol* 33:219–222. <https://doi.org/10.1097/WNF.0b013e3181ee7f63> 517
518
 81. Battistella PA, Ruffilli R, Cernetti R, et al (1993) A Placebo-Controlled Crossover Trial Using Trazodone in Pediatric Migraine. Headache *J Head Face Pain* 33:36–39. <https://doi.org/10.1111/j.1526-4610.1993.hed3301036.x> 519
520
 82. De Wit S, Cremers L, Hirsch D, et al (1999) Efficacy and safety of trazodone versus clorazepate in the treatment of HIV-positive subjects with adjustment disorders: A pilot study. *J Int Med Res* 27:223–232. <https://doi.org/10.1177/030006059902700502> 521
522
523
 83. Hudson JI, Pope HG, Keck PE, McElroy SL (1989) Treatment of bulimia nervosa with trazodone: Short-term response and 524

- long-term follow-up. *Clin Neuropharmacol* 12:. <https://doi.org/10.1097/00002826-198901001-00007> 525
84. Clouse RE, Lustman PJ, Eckert TC, et al (1987) Low-Dose Trazodone for Symptomatic Patients With Esophageal Contraction Abnormalities: A Double-Blind, Placebo-Controlled Trial. *Gastroenterology* 92:1027–1036. [https://doi.org/10.1016/0016-5085\(87\)90979-6](https://doi.org/10.1016/0016-5085(87)90979-6) 526
527
528
 85. Pigott TA, L'Heureux F, Rubenstein CS, et al (1992) A double-blind, placebo controlled study of trazodone in patients with obsessive-compulsive disorder. *J Clin Psychopharmacol* 12:156–162. <https://doi.org/10.1097/00004714-199206000-00002> 529
530
 86. Rickels K, Downing R, Schweizer E, Hassman H (1993) Antidepressants for the Treatment of Generalized Anxiety Disorder: A Placebo-Controlled Comparison of Imipramine, Trazodone, and Diazepam. *Arch Gen Psychiatry* 50:884–895. <https://doi.org/10.1001/archpsyc.1993.01820230054005> 531
532
533
 87. Le Bon O, Murphy JR, Staner L, et al (2003) Double-blind, placebo-controlled study of the efficacy of trazodone in alcohol post-withdrawal syndrome: Polysomnographic and clinical evaluations. *J Clin Psychopharmacol* 23:377–383. <https://doi.org/10.1097/01.jcp.0000085411.08426.d3> 534
535
536
 88. Bossini L, Coluccia A, Casolaro I, et al (2015) Off-Label Trazodone Prescription: Evidence, Benefits and Risks. *Curr Pharm Des* 21:3343–3351. <https://doi.org/10.2174/1381612821666150619092236> 537
538
 89. Sultzer DL, Gray KF, Gunay I, et al (2001) Does behavioral improvement with haloperidol or trazodone treatment depend on psychosis or mood symptoms in patients with dementia? *J Am Geriatr Soc* 49:1294–1300. <https://doi.org/10.1046/j.1532-5415.2001.49256.x> 539
540
541
 90. Camargos EF, Louzada LL, Quintas JL, et al (2014) Trazodone improves sleep parameters in Alzheimer disease patients: A randomized, double-blind, and placebo-controlled study. *Am J Geriatr Psychiatry* 22:1565–1574. <https://doi.org/10.1016/j.jagp.2013.12.174> 542
543
544
 91. Teri L, Logsdon RG, Peskind E, et al (2000) Treatment of agitation in AD: A randomized, placebo-controlled clinical trial. *Neurology* 55:1271–1278. <https://doi.org/10.1212/WNL.55.9.1271> 545
546
 92. Lebert F, Stekke W, Hasenbroekx C, Pasquier F (2004) Frontotemporal dementia: a randomised, controlled trial with trazodone. *Dement Geriatr Cogn Disord* 17:355–359. <https://doi.org/10.1159/000077171> 547
548
 93. Gonçalo AMG, Vieira-Coelho MA (2021) The effects of trazodone on human cognition: a systematic review. *Eur J Clin Pharmacol* 77:1623–1637. <https://doi.org/10.1007/S00228-021-03161-6> 549
550
 94. Revised guideline on clinical studies for Alzheimer's disease medicines | European Medicines Agency. <https://www.ema.europa.eu/en/news/revised-guideline-clinical-studies-alzheimers-disease-medicines>. Accessed 23 Dec 2021 551
552
553
 95. Trial drugs | MND-SMART. <https://mnd-smart.org/about/trial-drugs>. Accessed 17 Nov 2021 554
 96. Beswick E, Glasmacher SA, Daki, et al (2021) Prospective observational cohort study of factors influencing trial participation in people with motor neuron disease (FIT-participation-MND): a protocol. *BMJ Open* 11:. <https://doi.org/10.1136/BMJOPEN-2020-044996> 555
556
557
558